- In August 2024, Pfizer announced that its toxoid vaccine candidate PF-06425090, developed to prevent Clostridioides difficile infection, did not achieve the desired outcomes in its Phase III CLOVER trial. The vaccine demonstrated an efficacy rate of 31% in reducing infections among adults aged 50 and above; however, the results were not statistically significant, falling short of the study's primary endpoint
- In May 2024, ILiAD Biotechnologies reported that its intranasal pertussis vaccine candidate, BPZE1, showed positive results in a Phase 2b clinical trial. Conducted in children aged 6 to 17 across the UK, Australia, and Costa Rica, the trial assessed the vaccine's immune response and safety, both as a standalone treatment and in combination with the Tdap (Boostrix) vaccine, demonstrating promising immunogenicity and tolerability
- In December 2023, Panacea Biotec announced the launch of EasyFourPol, a fully liquid pentavalent vaccine (wP-IPV) in India. Designed to protect children against diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae type B infections, the vaccine offers a ready-to-use combination format, eliminating the need for on-site preparation by healthcare workers and enhancing the efficiency of immunization programs
- In January 2024, the National Pharmaceutical Pricing Authority (NPPA) granted an extension to the Serum Institute of India (SII), allowing the continued manufacturing of two tetanus toxoid formulations until December 31, 2024. This decision came after a request from SII to discontinue the products, ensuring the availability of these essential vaccines for public health use
